Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. - Wikidata - awgldk - TriplyDB

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

http://www.wikidata.org/entity/Q37480893

about

Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer Prostate cancer: ESMO Consensus Conference Guidelines 2012 Impact of treatment planning and delivery factors on gastrointestinal toxicity: an analysis of data from the RADAR prostate radiotherapy trial.Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis Radiation dose-volume effects in radiation-induced rectal injury.Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.Radiation treatment for patients with intermediate-risk prostate cancer.A review of update clinical results of carbon ion radiotherapy Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06.Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre.Late toxicity rates following definitive radiotherapy for prostate cancer.A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints.Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control.Bringing the heavy: carbon ion therapy in the radiobiological and clinical context.Carbon-ion radiation therapy for prostate cancer.Particle radiotherapy for prostate cancer.ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.Effect of modern, high-quality prostate intensity-modulated radiation therapy on outcome: Evidence from a community radiation oncology program.Radical radiotherapy for high-risk prostate cancer in older men Improved beam angle arrangement in intensity modulated proton therapy treatment planning for localized prostate cancer Accuracy of dose planning for prostate radiotherapy in the presence of metallic implants evaluated by electron spin resonance dosimetry Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.A retrospective study of late adverse events in proton beam therapy for prostate cancer.Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.Associations between volume changes and spatial dose metrics for the urinary bladder during local versus pelvic irradiation for prostate cancer.Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia.Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities

P2860

Q26772255-97D30C66-A042-46BB-BB6B-222CC65DA5E7 Q27022847-3446D2E5-4B8C-4305-BFC2-F04DE4CE30F1 Q30877686-BA2244FC-0228-428F-A924-F580721251BE Q34238364-CD362848-1362-444C-9F1C-2CC55B52A982 Q34500966-FA81F598-D8F5-4D69-9D9C-A25296F85CD5 Q35870610-61E67845-02B1-40C9-807F-86842E85D1CE Q35979481-166EAF2D-5053-49F9-AE0C-E746A5237874 Q35992830-26A83E22-6CB4-4FE6-9218-13195A1780B5 Q36119520-01C7277B-8B3F-4A16-8FC4-087B5D15D87E Q36145910-1EAB1DAE-459F-49A8-B3E1-36C47D596F9E Q36156751-59C4C386-7630-4EE6-93C3-E29DB8D6754D Q36908059-44B96CDA-EAC0-4984-A6F5-F76191D70282 Q37137423-1E565705-CAC0-4E95-9D3D-6FB58E36228E Q37256972-B54A1BD3-0DA3-48FA-9A9E-28C6F53917FC Q37386325-B0321042-D977-4A27-BD76-69E237F93080 Q37427059-ADADE134-5DCB-4743-A0BF-A0BA95893D0E Q37727823-C4C10E9C-0004-41F9-8AEE-1A98F5F95AD0 Q37982799-FDA0F633-F0DA-46A8-8675-D052D6DBF00F Q38259506-576EEF91-8ECF-42B6-825F-A30CE79CCCD2 Q39456200-3B9AC40D-C024-418F-9403-CC1B2906E6F1 Q41162265-C31859CA-683E-4804-A701-E4A4438D0BBA Q41334584-AB812F80-8CE0-4CA0-99D9-E06E993E6B95 Q41416202-D82B5EE7-2EE0-42FF-BD37-16B80E1E221A Q42097767-8A055DC6-C388-4B62-9AF9-6DA39D96C710 Q42199585-F9C364FC-6DD6-4C8C-BFD1-7ABD2D53A9F9 Q42376337-E2EBFE5A-B95E-4764-B1E4-DDB5096B5989 Q42709732-5C2C3F1B-6C11-4788-B2C0-B591378CB1EE Q44124651-F2FF429F-0D22-406D-B830-73F8DE23B708 Q46439191-DD19CED9-4B1E-4F6B-A19D-41B2B29174EB Q48772363-F2CCCB82-FC9F-4C19-B478-C1DAED5D245E Q57179181-7D210D12-2F24-4B0D-80A2-284EEA5C1C4A

P2860

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

http://www.wikidata.org/entity/Q37480893

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Long-term toxicity following 3 ...... se I/II dose escalation study.

@en

Long-term toxicity following 3 ...... se I/II dose escalation study.

@nl

type

label

Long-term toxicity following 3 ...... se I/II dose escalation study.

@en

Long-term toxicity following 3 ...... se I/II dose escalation study.

@nl

prefLabel

Long-term toxicity following 3 ...... se I/II dose escalation study.

@en

Long-term toxicity following 3 ...... se I/II dose escalation study.

@nl

P1433

Q37480893-5B5E2441-679A-460B-BFAE-9FE13E4B9079

P1476

Q37480893-F426FE05-D6CA-4ED5-8C60-5C9A263B397B

P2093

Q37480893-0DD85B79-584A-4A80-BAF6-536EAE4BF9DD

Q37480893-178D12A6-8CF9-40AA-8DEC-B8E02A7A7C81

Q37480893-36281122-5992-4838-B612-04510C9FEC56

Q37480893-63F68593-EDC4-4A36-8643-A5926BB36B08

Q37480893-80564541-8115-4D73-BB54-BB0C72DA5D19

Q37480893-83CB292B-00B2-41C9-9468-46D23C6B0CDE

Q37480893-84EB0B43-0ABC-448F-A166-0CE29EA8A2C3

Q37480893-C13767F6-A0E1-49B7-8E20-7577D79A4F6F

Q37480893-EE46B928-2BC3-48FB-9636-87F5B3CA51EB

P2860

Q37480893-01BB0AD0-B8A8-49C3-9EA0-3DFB3070949E

Q37480893-46D9A3F0-79B5-49AD-A8F3-A15346D3D2D6

Q37480893-929E3A5D-B2D7-4607-A017-046ACA0A6551

Q37480893-954C49FB-EE9C-4773-9533-232BB3620E87

Q37480893-BBEDB8CB-D87F-487F-B1EB-E7E9CF808EEA

Q37480893-CEBC85AD-25B8-4F45-8C54-EE293880BDA4

Q37480893-D21D729B-098E-4703-B138-D11306483BB3

Q37480893-EA446B73-1720-489D-9A6B-CF094A03274A

Q37480893-EF9BCB78-3E27-4DE6-8A11-360BA0011817

Q37480893-F5828F9B-FF32-491E-9740-74FFC88FED59

P304

Q37480893-C76A0C91-8EA6-46B0-90D7-CFF269EDD7FC

P31

Q37480893-72DBDB68-D4F9-41A7-A742-52B4B61B6DED

P356

Q37480893-DBE96073-C247-4CE2-BF30-927BB972EC5E

P407

Q37480893-D2DA90F0-BABE-4E58-8BC5-7F05F5F57F0B

P433

Q37480893-F16ACBB6-DA77-468C-9F3A-024EFE7826FF

P478

Q37480893-6548A07E-3909-4F49-9F6B-2E936F9E82B2

P50

Q37480893-115B69BA-269F-44BE-A9F7-4589C33F6FD4

P577

Q37480893-64E4DDBF-E820-4650-9D96-4E2078AE6024

P5875

Q37480893-D3387F7E-277D-4F47-9267-0E21549FD40C

P698

Q37480893-8EA7529D-3731-45B8-8C52-29955442751A

P921

Q37480893-1A32D24E-5A0C-4B05-8023-C083BF7C0A14

P932

Q37480893-53F580D5-B57E-4136-8514-E340D587D979

P356

J.IJROBP.2009.01.062

P1433

International Journal of Radiation Oncology Biology Physics

P1476

Long-term toxicity following 3 ...... se I/II dose escalation study.

@en

P2093

Arnold M Markoe

http://www.w3.org/2001/XMLSchema#string

Howard M Sandler

http://www.w3.org/2001/XMLSchema#string

James D Cox

http://www.w3.org/2001/XMLSchema#string

Janice Ryu

http://www.w3.org/2001/XMLSchema#string

Jeff M Michalski

http://www.w3.org/2001/XMLSchema#string

Kyounghwa Bae

http://www.w3.org/2001/XMLSchema#string

Matthew B Parliament

http://www.w3.org/2001/XMLSchema#string

Richard K Valicenti

http://www.w3.org/2001/XMLSchema#string

William Straube

http://www.w3.org/2001/XMLSchema#string

P2860

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

Is alpha/beta for prostate tumors really low?

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer.

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

P304

14-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJROBP.2009.01.062

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26647791

http://www.w3.org/2001/XMLSchema#string

P698

19577865

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

2795116

http://www.w3.org/2001/XMLSchema#string